MARLBOROUGH, Mass., May 16, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule ofkey presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris, on May 22-25.
During the late-breaking sessions
Other presentations of interest include two sub-analyses from the REPRISE III randomized trial, also featuring the LOTUS Valve: multivariate predictors of early and late stroke after implantation and gender-related differences in clinical presentation and outcomes after TAVI. Data regarding the matched comparison of anticoagulation vs. antiplatelet therapy after LAA closure with the WATCHMAN™ Left Atrial Appendage Device will also be presented.
"We feel that this year's EuroPCR program will serve as a backdrop for engaging dialogue around data milestones that demonstrate the strength of our cardiovascular portfolio," said Professor Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. "Additionally, we have been anticipating the outcomes from multiple studies being presented around our SYNERGY™ Bioabsorbable Polymer Stent, including further insight into assessing outcomes associated with patients presenting with complex disease states, high bleeding risk and shorter dual anti-platelet regimens."
SCHEDULE OF PRESENTATIONS OF INTEREST (listed chronologically)
Tuesday, May 22
Wednesday, May 23
Thursday, May 24
All events are listed in Central European Summer Time (CEST) and take place at the Palais des Congrès. For additional details about Boston Scientific data presentations and sponsored symposia, go to www.bostonscientific.eu/europcr-2018 or visit the Boston Scientific booth located on Level 1, Hall Passy F21. For more information about Boston Scientific at EuroPCR, please follow @BSC_EU_Heart.
*The LOTUS Valve system is currently not available for use or sale. **In the U.S., the Agent™ Paclitaxel-Coated balloon catheter is investigational and not available for sale.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter, LinkedIn and Facebook.
Timette Nevala U.S. Media(763) 494-1284 (office) Timette.Nevala@bsci.com
Rainer PusterEuropean Media+49 (0) 1754347057 Rainer.Puster@bsci.com
Susie Lisa, CFAInvestor Relations(508) 683-5565 (office) BSXInvestorRelations@bsci.com
View original content:http://www.prnewswire.com/news-releases/boston-scientific-announces-schedule-of-presentations-at-europcr-2018-300649297.html
SOURCE Boston Scientific Corporation
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All